Pharmacist phone calls could boost lifesaving statin use in heart patients

NCT ID NCT06551701

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study tests whether having a pharmacist call both patients with heart disease and their doctors can increase the use of high-intensity statins—powerful cholesterol-lowering drugs that prevent future heart problems. The trial includes adults aged 18 to 75 with atherosclerotic cardiovascular disease who are not already on a moderate or high-intensity statin. The goal is to see if this simple, low-cost intervention can improve medication use and reduce the risk of heart attacks and strokes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pharmacist-led intervention (calls to patients and providers)

What this could lead to

If successful, this approach could help more patients with heart disease get the recommended statin therapy, potentially reducing heart attacks and strokes.

What could go wrong

This is a small, early-stage trial focused on feasibility, not on directly measuring health outcomes. The intervention may not change prescribing habits or improve patient health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Carelon Research

    Wilmington, Delaware, 19801, United States

  • Duke Clinical Research Institute

    Durham, North Carolina, 27701, United States